171 related articles for article (PubMed ID: 8820427)
1. Metoprolol metabolism via cytochrome P4502D6 in ethnic populations.
Johnson JA; Burlew BS
Drug Metab Dispos; 1996 Mar; 24(3):350-5. PubMed ID: 8820427
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.
Bramer SL; Suri A
Clin Pharmacokinet; 1999; 37 Suppl 2():41-51. PubMed ID: 10702886
[TBL] [Abstract][Full Text] [Related]
3. CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences.
Johnson JA; Herring VL; Wolfe MS; Relling MV
J Pharmacol Exp Ther; 2000 Sep; 294(3):1099-105. PubMed ID: 10945865
[TBL] [Abstract][Full Text] [Related]
4. Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6-Mediated Drug-Drug Interactions on Tramadol and O-Desmethyltramadol Exposures via Allosteric and Competitive Inhibition.
Long T; Cristofoletti R; Cicali B; Michaud V; Dow P; Turgeon J; Schmidt S
J Clin Pharmacol; 2022 Jan; 62(1):76-86. PubMed ID: 34383318
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of hepatocytes for evaluating the genetic polymorphism of CYP2D6 substrates.
Komura H; Iwaki M
Xenobiotica; 2005 Jun; 35(6):575-87. PubMed ID: 16192109
[TBL] [Abstract][Full Text] [Related]
6. Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration.
Sowinski KM; Lima JJ; Burlew BS; Massie JD; Johnson JA
Br J Clin Pharmacol; 1996 Sep; 42(3):339-46. PubMed ID: 8877025
[TBL] [Abstract][Full Text] [Related]
7. A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics.
Blake CM; Kharasch ED; Schwab M; Nagele P
Clin Pharmacol Ther; 2013 Sep; 94(3):394-9. PubMed ID: 23665868
[TBL] [Abstract][Full Text] [Related]
8. The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity.
Wennerholm A; Dandara C; Sayi J; Svensson JO; Abdi YA; Ingelman-Sundberg M; Bertilsson L; Hasler J; Gustafsson LL
Clin Pharmacol Ther; 2002 Jan; 71(1):77-88. PubMed ID: 11823760
[TBL] [Abstract][Full Text] [Related]
9. Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6.
Ellis SW; Hayhurst GP; Lightfoot T; Smith G; Harlow J; Rowland-Yeo K; Larsson C; Mahling J; Lim CK; Wolf CR; Blackburn MG; Lennard MS; Tucker GT
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):565-71. PubMed ID: 10642515
[TBL] [Abstract][Full Text] [Related]
10. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects.
Yoon YR; Cha IJ; Shon JH; Kim KA; Cha YN; Jang IJ; Park CW; Shin SG; Flockhart DA; Shin JG
Clin Pharmacol Ther; 2000 May; 67(5):567-76. PubMed ID: 10824636
[TBL] [Abstract][Full Text] [Related]
11. Metoprolol-pridopidine drug-drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease.
Rabinovich-Guilatt L; Steiner L; Hallak H; Pastino G; Muglia P; Spiegelstein O
Br J Clin Pharmacol; 2017 Oct; 83(10):2214-2224. PubMed ID: 28449367
[TBL] [Abstract][Full Text] [Related]
12. The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine.
Yasuda SU; Zannikos P; Young AE; Fried KM; Wainer IW; Woosley RL
Br J Clin Pharmacol; 2002 May; 53(5):519-25. PubMed ID: 11994058
[TBL] [Abstract][Full Text] [Related]
13. Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination.
Laurent-Kenesi MA; Funck-Brentano C; Poirier JM; Decolin D; Jaillon P
Br J Clin Pharmacol; 1993 Dec; 36(6):531-8. PubMed ID: 12959269
[TBL] [Abstract][Full Text] [Related]
14. CYP2D6 allele frequencies in Korean population, comparison with East Asian, Caucasian and African populations, and the comparison of metabolic activity of CYP2D6 genotypes.
Byeon JY; Kim YH; Lee CM; Kim SH; Chae WK; Jung EH; Choi CI; Jang CG; Lee SY; Bae JW; Lee YJ
Arch Pharm Res; 2018 Sep; 41(9):921-930. PubMed ID: 30191460
[TBL] [Abstract][Full Text] [Related]
15. Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans.
Eap CB; Lessard E; Baumann P; Brawand-Amey M; Yessine MA; O'Hara G; Turgeon J
Pharmacogenetics; 2003 Jan; 13(1):39-47. PubMed ID: 12544511
[TBL] [Abstract][Full Text] [Related]
16. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians.
Droll K; Bruce-Mensah K; Otton SV; Gaedigk A; Sellers EM; Tyndale RF
Pharmacogenetics; 1998 Aug; 8(4):325-33. PubMed ID: 9731719
[TBL] [Abstract][Full Text] [Related]
17. Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers.
Jin SK; Chung HJ; Chung MW; Kim JI; Kang JH; Woo SW; Bang S; Lee SH; Lee HJ; Roh J
J Clin Pharm Ther; 2008 Oct; 33(5):567-73. PubMed ID: 18834373
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
[TBL] [Abstract][Full Text] [Related]
19. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
Bertilsson L; Meese CO; Yue QY; Dahl ML; Ingelman-Sundberg M; Johansson I; Säwe J; Eichelbaum M
Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167
[TBL] [Abstract][Full Text] [Related]
20. Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol.
Koytchev R; Alken RG; Vlahov V; Kirkov V; Kaneva R; Thyroff-Friesinger U; Rehak E
Eur J Clin Pharmacol; 1998 Aug; 54(6):469-74. PubMed ID: 9776437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
